Composition
- Active substance
- casopitant
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zunrisa
- Active substance
- casopitant
- Therapeutic area
- Vomiting, Postoperative Nausea and Vomiting, Cancer
- Marketing authorisation holder
- Glaxo Group Ltd
- Status
- Application withdrawn
- EMA product number
- EMEA/H/C/001040
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment
- No
- Additional monitoring
- No
- Patient safety information
- No